公开(公告)号：US20210238296A1

公开(公告)日：2021-08-05

申请号：US17051205

申请日：2019-05-03

Applicant: GENMAB B.V.

Inventor： Rob DE JONG ,  Frank BEURSKENS ,  Simone OOSTINDIE ,  Aran Frank LABRIJN ,  Kristin STRUMANE ,  Janine SCHUURMAN ,  Bart-Jan DE KREUK

IPC: C07K16/28 ,  A61K45/06

Abstract: Provided herein are combinations of first and second antibodies having modified Fc effector functions resulting from amino acid substitutions in the Fc region, the amino acid substitutions allow for co-dependent activation of effector functions such as CDC and/or ADCC. Also provided are combinations of first and second antibodies having agonistic activity or enhanced agonistic activity resulting from amino acid substitutions in the Fc region where the agonistic activity is co-dependent of both a first and second antibodies.

公开(公告)号：US20210107988A1

公开(公告)日：2021-04-15

申请号：US16963701

申请日：2019-01-24

Applicant: GENMAB B.V.

Inventor： Simone OOSTINDIE ,  Andreas HOLLENSTEIN ,  Frank BEURSKENS ,  Kristin STRUMANE ,  Janine SCHUURMAN ,  Rob DE JONG

IPC: C07K16/28 ,  A61P35/00

Abstract: The present invention relates to combination therapy involving two or more Fc region-containing antigen-binding polypeptides, such as antibodies, wherein the polypeptides have been modified such that hetero-oligomerization between the polypeptides is strongly favored over homo-oligomerization when the polypeptides are bound to their corresponding target antigens. The invention also relates to polypeptides, compositions, kits and devices suitable for use in the combination therapy of the invention.